LOGO
LOGO

Quick Facts

Pfizer Reaffirms Transparency Commitment On COVID-19 Vaccine Data

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Pfizer Inc. (PFE), Wednesday reaffirmed its pledge to provide transparent and consistent disclosures of its COVID-19 vaccine research, emphasizing the integrity of its ongoing studies.

Chairman and CEO Dr. Albert Bourla credited Operation Warp Speed under President Trump's leadership with driving mRNA vaccine innovation, preventing an estimated 14 million deaths worldwide, saving over $1 trillion in healthcare costs, and establishing a platform for future advances, including cancer research.

Bourla welcomed calls for transparency, noting that data from Pfizer's vaccine has been published in more than 600 peer-reviewed studies and submitted to regulators in 130 countries, all of which approved its use.

The company said additional updates, including data on its latest vaccine strain approved by the FDA, will be released soon. Pfizer underscored that transparency remains central to sustaining public trust.

PFE is currently trading at $24.79, down $0.19 or 0.77 percent on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19